Metrics to compare | OSTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOSTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −7.6x | −0.3x | |
PEG Ratio | 0.04 | 3.74 | 0.00 | |
Price/Book | −5.3x | 5.2x | 2.6x | |
Price / LTM Sales | - | 4.2x | 3.1x | |
Upside (Analyst Target) | - | 41.4% | 50.4% | |
Fair Value Upside | Unlock | 4.0% | 6.4% | Unlock |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.